scholarly journals Retrospective Seroepidemiological Survey for Human Babesiosis in an Area in Japan Where a Tick-Borne Disease is Endemic

2003 ◽  
Vol 65 (3) ◽  
pp. 335-340 ◽  
Author(s):  
Satoru ARAI ◽  
Masayoshi TSUJI ◽  
Ikuo KAIHO ◽  
Haruka MURAYAMA ◽  
Aya ZAMOTO ◽  
...  
Keyword(s):  
Tick Borne Disease ◽  
Human Babesiosis

scholarly journals Human babesiosis, an emerging tick-borne disease in the People’s Republic of China

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Xia Zhou ◽  
Shang Xia ◽  
Ji-Lei Huang ◽  
Ernest Tambo ◽  
Hong-Xiang Zhuge ◽  
...  
Keyword(s):  
People’S Republic Of China ◽  
People's Republic Of China ◽  
Republic Of China ◽  
Tick Borne Disease ◽  
Human Babesiosis

scholarly journals Human babesiosis, an emerging tick-borne disease in the People¿s Republic of China

2014 ◽  
Vol 7 (1) ◽  
pp. 509
Author(s):  
Xia Zhou ◽  
Shang Xia ◽  
Ji-Lei Huang ◽  
Ernest Tambo ◽  
Hong-Xiang Ge ◽  
...  
Keyword(s):  
Republic Of China ◽  
The People ◽  
Tick Borne Disease ◽  
Human Babesiosis

Human babesiosis: an emerging tick-borne disease

2000 ◽  
Vol 30 (12-13) ◽  
pp. 1323-1337 ◽  
Author(s):  
A.M. Kjemtrup ◽  
P.A. Conrad
Keyword(s):  
Tick Borne Disease ◽  
Human Babesiosis

scholarly journals Treatment of Human Babesiosis: Then and Now

Pathogens ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1120
Author(s):  
Isaline Renard ◽  
Choukri Ben Mamoun
Keyword(s):  
Management Strategies ◽  
Health Concern ◽  
Combination Therapies ◽  
Public Health Concern ◽  
Apicomplexan Parasites ◽  
Biological Criteria ◽  
Tick Borne Disease ◽  
Rapid Emergence ◽  
Review Current ◽  
Human Babesiosis

Babesiosis is an emerging tick-borne disease caused by apicomplexan parasites of the genus Babesia. With its increasing incidence worldwide and the risk of human-to-human transmission through blood transfusion, babesiosis is becoming a rising public health concern. The current arsenal for the treatment of human babesiosis is limited and consists of combinations of atovaquone and azithromycin or clindamycin and quinine. These combination therapies were not designed based on biological criteria unique to Babesia parasites, but were rather repurposed based on their well-established efficacy against other apicomplexan parasites. However, these compounds are associated with mild or severe adverse events and a rapid emergence of drug resistance, thus highlighting the need for new therapeutic strategies that are specifically tailored to Babesia parasites. Herein, we review ongoing babesiosis therapeutic and management strategies and their limitations, and further review current efforts to develop new, effective, and safer therapies for the treatment of this disease.

scholarly journals Evidence for vesicle-mediated antigen export by the human pathogen Babesia microti

2019 ◽  
Vol 2 (3) ◽  
pp. e201900382 ◽  
Author(s):  
Jose Thekkiniath ◽  
Nicole Kilian ◽  
Lauren Lawres ◽  
Meital A Gewirtz ◽  
Morven M Graham ◽  
...  
Keyword(s):  
Parasitophorous Vacuole ◽  
Apicomplexan Parasite ◽  
Babesia Microti ◽  
Cell Fractionation ◽  
Tick Borne Disease ◽  
Immunodominant Antigens ◽  
Close Relatives ◽  
Primary Agent ◽  
Human Babesiosis ◽  
Secreted Antigens

The apicomplexan parasite Babesia microti is the primary agent of human babesiosis, a malaria-like illness and potentially fatal tick-borne disease. Unlike its close relatives, the agents of human malaria, B. microti develops within human and mouse red blood cells in the absence of a parasitophorous vacuole, and its secreted antigens lack trafficking motifs found in malarial secreted antigens. Here, we show that after invasion of erythrocytes, B. microti undergoes a major morphogenic change during which it produces an interlacement of vesicles (IOV); the IOV system extends from the plasma membrane of the parasite into the cytoplasm of the host erythrocyte. We developed antibodies against two immunodominant antigens of the parasite and used them in cell fractionation studies and fluorescence and immunoelectron microscopy analyses to monitor the mode of secretion of B. microti antigens. These analyses demonstrate that the IOV system serves as a major export mechanism for important antigens of B. microti and represents a novel mechanism for delivery of parasite effectors into the host by this apicomplexan parasite.

Current Challenges in the Development of Vaccines and Drugs Against Emerging Vector-borne Diseases

2019 ◽  
Vol 26 (16) ◽  
pp. 2974-2986 ◽  
Author(s):  
Kwang-sun Kim
Keyword(s):  
New Host ◽  
In Vivo Models ◽  
Vector Borne Diseases ◽  
Novel Drugs ◽  
Huge Impact ◽  
Tick Borne Disease ◽  
Vector Borne ◽  
Living Organisms

Vectors are living organisms that transmit infectious diseases from an infected animal to humans or another animal. Biological vectors such as mosquitoes, ticks, and sand flies carry pathogens that multiply within their bodies prior to delivery to a new host. The increased prevalence of Vector-Borne Diseases (VBDs) such as Aedes-borne dengue, Chikungunya (CHIKV), Zika (ZIKV), malaria, Tick-Borne Disease (TBD), and scrub typhus has a huge impact on the health of both humans and livestock worldwide. In particular, zoonotic diseases transmitted by mosquitoes and ticks place a considerable burden on public health. Vaccines, drugs, and vector control methods have been developed to prevent and treat VBDs and have prevented millions of deaths. However, development of such strategies is falling behind the rapid emergence of VBDs. Therefore, a comprehensive approach to fighting VBDs must be considered immediately. In this review, I focus on the challenges posed by emerging outbreaks of VBDs and discuss available drugs and vaccines designed to overcome this burden. Research into promising drugs needs to be upgraded and fast-tracked, and novel drugs or vaccines being tested in in vitro and in vivo models need to be moved into human clinical trials. Active preventive tactics, as well as new and upgraded diagnostics, surveillance, treatments, and vaccination strategies, need to be monitored constantly if we are to manage VBDs of medical importance.

Sign in / Sign up

Export Citation Format

Share Document